Coherus Oncology (CHRS) Debt/Assets Ratio: History & Chart

Coherus Oncology, Inc.(CHRS)

Biotechnology · Redwood City, CA

$1.12-0.04 (-3.45%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

Redwood City, CA

144 employees

www.coherus.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dennis Lanfear

View full financials

CHRS Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

19.72%

DEBT TO ASSETS RATIO AVG TTM

14.60%

DEBT TO ASSETS RATIO AVG 3Y

48.23%

DEBT TO ASSETS RATIO AVG 5Y

59.98%

DEBT TO ASSETS RATIO AVG 10Y

61.31%

DEBT TO ASSETS RATIO AVG 15Y

N/A

DEBT TO ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+35.11%

CURRENT VS 3Y AVG

-59.11%

CURRENT VS 5Y AVG

-67.12%

CURRENT VS 10Y AVG

-67.83%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11%

median of 462 covered companies

CURRENT VS SECTOR MEDIAN

+17829.51%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Coherus Oncology, Inc. (CHRS)	$173.04M	19.72%	14.60%	48.23%	59.98%
Compass Therapeutics, Inc. (CMPX)vs ›	$172.99M	0.05%	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$174.17M	0.22%	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$176.96M	0.29%	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$179.70M	0.00%	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$162.82M	0.06%	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$184.12M	0.26%	N/A	N/A	N/A
Inogen, Inc. (INGN)vs ›	$160.82M	0.06%	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$153.84M	0.27%	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.97M	0.00%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Coherus Oncology, Inc. (CHRS)

$173.04M

19.72%

14.60%

48.23%

59.98%

Compass Therapeutics, Inc. (CMPX)vs ›

$172.99M

0.05%

N/A

Precision BioSciences, Inc. (DTIL)vs ›

$174.17M

0.22%

N/A

Cue Biopharma, Inc. (CUE)vs ›

$176.96M

0.29%

N/A

Canton Strategic Holdings Inc (CNTN)vs ›

$179.70M

0.00%

N/A

ALX Oncology Holdings Inc. (ALXO)vs ›

$162.82M

0.06%

N/A

Journey Medical Corporation (DERM)vs ›

$184.12M

0.26%

N/A

Inogen, Inc. (INGN)vs ›

$160.82M

0.06%

N/A

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$153.84M

0.27%

N/A

Eledon Pharmaceuticals, Inc. (ELDN)vs ›

$192.97M

0.00%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Coherus Oncology, Inc. (CHRS)?

The debt to assets ratio for CHRS stock is 19.72%.

Is Coherus Oncology, Inc.'s debt to assets ratio high or low?

The debt to assets ratio of 19.72% is 67% below its 5-year average of 59.98%, near the low end of its 5-year range (7.88%–119.24%).

What is the TTM average debt to assets ratio for Coherus Oncology, Inc. (CHRS)?

The TTM average debt to assets ratio for CHRS stock is 14.60%.

What is the 3Y average debt to assets ratio for Coherus Oncology, Inc. (CHRS)?

The 3Y average debt to assets ratio for CHRS stock is 48.23%.

What is the 5Y average debt to assets ratio for Coherus Oncology, Inc. (CHRS)?

The 5Y average debt to assets ratio for CHRS stock is 59.98%.

What is the 10Y average debt to assets ratio for Coherus Oncology, Inc. (CHRS)?

The 10Y average debt to assets ratio for CHRS stock is 61.31%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	19.72%
2026-03-31	20.44%
2025-12-31	15.61%
2025-09-30	7.88%
2025-06-30	9.34%
2025-03-31	72.74%
2024-12-31	60.17%
2024-09-30	53.44%
2024-06-30	44.21%
2024-03-31	63.02%
2023-12-31	76.37%
2023-09-30	82.00%
2023-06-30	102.06%
2023-03-31	119.24%
2022-12-31	99.91%
2022-09-30	87.26%
2022-06-30	79.08%
2022-03-31	72.52%
2021-12-31	61.68%
2021-09-30	56.46%
2021-06-30	56.51%
2021-03-31	60.23%
2020-12-31	49.56%
2020-09-30	51.48%
2020-06-30	54.63%
2020-03-31	40.76%
2019-12-31	46.13%
2019-09-30	54.30%
2019-06-30	73.68%
2019-03-31	99.56%
2018-12-31	103.64%
2018-09-30	72.60%
2018-06-30	54.34%
2018-03-31	79.37%
2017-12-31	62.36%
2017-09-30	53.36%
2017-06-30	58.59%
2017-03-31	44.21%
2016-12-31	56.17%
2016-09-30	51.95%
2016-06-30	39.68%
2016-03-31	43.90%
2015-12-31	0.00%
2015-09-30	0.00%
2015-06-30	0.00%
2015-03-31	0.00%
2014-12-31	0.00%
2014-09-30	1.78%
2014-06-30	1.30%
2014-03-31	9.63%
2013-12-31	8.86%

DATE

DEBT TO ASSETS RATIO

2026-06-30

19.72%

2026-03-31

20.44%

2025-12-31

15.61%

2025-09-30

7.88%

2025-06-30

9.34%

2025-03-31

72.74%

2024-12-31

60.17%

2024-09-30

53.44%

2024-06-30

44.21%

2024-03-31

63.02%

2023-12-31

76.37%

2023-09-30

82.00%

2023-06-30

102.06%

2023-03-31

119.24%

2022-12-31

99.91%

2022-09-30

87.26%

2022-06-30

79.08%

2022-03-31

72.52%

2021-12-31

61.68%

2021-09-30

56.46%

2021-06-30

56.51%

2021-03-31

60.23%

2020-12-31

49.56%

2020-09-30

51.48%

2020-06-30

54.63%

2020-03-31

40.76%

2019-12-31

46.13%

2019-09-30

54.30%

2019-06-30

73.68%

2019-03-31

99.56%

2018-12-31

103.64%

2018-09-30

72.60%

2018-06-30

54.34%

2018-03-31

79.37%

2017-12-31

62.36%

2017-09-30

53.36%

2017-06-30

58.59%

2017-03-31

44.21%

2016-12-31

56.17%

2016-09-30

51.95%

2016-06-30

39.68%

2016-03-31

43.90%

2015-12-31

0.00%

2015-09-30

0.00%

2015-06-30

0.00%

2015-03-31

0.00%

2014-12-31

0.00%

2014-09-30

1.78%

2014-06-30

1.30%

2014-03-31

9.63%

2013-12-31

8.86%

Debt to Assets Ratio: 19.72%

CHRS Debt to Assets Ratio

CHRS Average Debt to Assets Ratio Chart

CHRS Current vs Average Debt to Assets Ratio Chart

CHRS Debt to Assets Ratio Metrics

CHRS Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

CHRS Debt to Assets Ratio History

Related Metrics